M
Malcolm K. Brenner
Researcher at Center for Cell and Gene Therapy
Publications - 632
Citations - 50064
Malcolm K. Brenner is an academic researcher from Center for Cell and Gene Therapy. The author has contributed to research in topics: Antigen & Cytotoxic T cell. The author has an hindex of 109, co-authored 606 publications receiving 45233 citations. Previous affiliations of Malcolm K. Brenner include St. Jude Children's Research Hospital & Northwick Park Hospital.
Papers
More filters
Journal ArticleDOI
Transplantability and therapeutic effects of bone marrow-derived mesenchymal cells in children with osteogenesis imperfecta
Edwin M. Horwitz,Darwin J. Prockop,Lorraine A. Fitzpatrick,Winston W.K. Koo,Patricia L. Gordon,Michael D. Neel,Michael D. Sussman,Paul J. Orchard,Jeffrey C. Marx,Reed E. Pyeritz,Malcolm K. Brenner +10 more
TL;DR: Improvements in total body bone mineral content and growth velocity were associated with increases in growth velocity and reduced frequencies of bone fracture, indicating the feasibility of allogeneic bone marrow transplantation in the treatment of osteogenesis imperfecta and perhaps other mesenchymal stem cell disorders as well.
Journal ArticleDOI
Inducible apoptosis as a safety switch for adoptive cell therapy
Antonio Di Stasi,Siok-Keen Tey,Gianpietro Dotti,Yuriko Fujita,Alana A. Kennedy-Nasser,Caridad Martinez,Karin Straathof,Enli Liu,April G. Durett,Bambi Grilley,Hao Liu,Conrad Russell Y. Cruz,Barbara Savoldo,Adrian P. Gee,John Schindler,Robert A. Krance,Helen E. Heslop,David M. Spencer,Cliona M. Rooney,Malcolm K. Brenner +19 more
TL;DR: The inducible T-cell safety switch based on the fusion of human caspase 9 to a modified human FK-binding protein, allowing conditional dimerization may increase the safety of cellular therapies and expand their clinical applications.
Journal ArticleDOI
A distinct "side population" of cells with high drug efflux capacity in human tumor cells.
C. Hirschmann-Jax,Aaron E. Foster,Gerald Wulf,Gerald Wulf,Jed G. Nuchtern,T. W. Jax,U. Gobel,Margaret A. Goodell,Malcolm K. Brenner +8 more
TL;DR: A distinct SP was found in neuroblastoma cells from 15 of 23 patients and showed evidence for asymmetric division, generating both SP and non-SP progeny, suggesting that this phenotype defines a class of cancer stem cells with inherently high resistance to chemotherapeutic agents that should be targeted during the treatment of malignant disease.
Journal ArticleDOI
Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr-virus-related lymphoproliferation.
Cliona M. Rooney,Catherine Y.C. Ng,Susan K. Loftin,Colton Smith,Congfen Li,Robert A. Krance,Malcolm K. Brenner,Helen E. Heslop +7 more
TL;DR: EBV-specific donor-type T-cell lines seem to offer safe and effective therapy for control of EBV-associated lymphoproliferation in patients with EBV reactivation after bone-marrow transplantation.
Journal ArticleDOI
Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma
Martin Pule,Barbara Savoldo,G. Doug Myers,G. Doug Myers,Claudia Rossig,Heidi V. Russell,Heidi V. Russell,Gianpietro Dotti,Gianpietro Dotti,M. Helen Huls,Enli Liu,Adrian P. Gee,Adrian P. Gee,Zhuyong Mei,Eric Yvon,Heidi L. Weiss,Hao Liu,Cliona M. Rooney,Cliona M. Rooney,Helen E. Heslop,Helen E. Heslop,Malcolm K. Brenner,Malcolm K. Brenner +22 more
TL;DR: It is shown in individuals with neuroblastoma that EBV-specific CTLs expressing a chimeric GD2-specific receptor indeed survive longer than T cells activated by the CD3-specific antibody OKT3 and expressing the same chimeric receptor but lacking virus specificity.